Every 424B that PDS Biotechnology Corporation (PDSB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PDSB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PDSB filings page.
PDS Biotechnology Corporation is registering for resale up to 13,315,823 shares of common stock on behalf of YA II PN, LTD. These shares consist of 2,158,274 shares issuable upon exercise of a warrant with a cash exercise price of $1.1824 per share and up to 11,157,549 shares issuable upon conversion of a $6,000,000 promissory note.
The note was sold at a 4% original issue discount for proceeds of $5,760,000, bears interest at 10% per annum, and matures 12 months after the June 15, 2026 closing. It is convertible only if a payment default occurs, subject to a 4.99% beneficial ownership cap and a 19.99% issuance cap unless stockholder approval is obtained under Nasdaq Rule 5635(d). The warrant is exercisable six months after closing and remains outstanding for five years with similar ownership and exchange caps.
PDS Biotechnology will not receive proceeds from any resale of these shares by the selling stockholder, but will receive cash only if the warrant is exercised for cash, which it intends to use for general corporate purposes. As of July 2, 2026, 55,921,806 shares of common stock were outstanding out of 150,000,000 authorized, and the company also maintains a separate at-the-market program of up to $50,000,000 in common stock sales through affiliated agents.
PDS Biotechnology Corporation filed a prospectus supplement to offer up to $50,000,000 of its common stock in an at-the-market offering under a Sales Agreement with Yorkville Securities and B. Riley Securities.
The supplement states the Agents will act as sales agents or principals and receive a 3.0% commission. The company recently closed a financing with YA II that included a $6,000,000 promissory note and a warrant to purchase 2,158,274 shares at an exercise price of $1.1824 per share. The company agreed to file a registration statement to register resale of shares issuable on conversion or exercise. The prospectus shows an illustrative post-offering outstanding share count of up to 103,434,701 shares based on specified assumptions.
PDS Biotechnology (PDSB) launched a primary best‑efforts offering of 5,741,000 shares of common stock at $0.91 per share, together with pre‑funded warrants to purchase up to 59,000 shares at $0.9099 and common warrants to purchase up to 5,800,000 shares at a $1.00 exercise price. This supplement also registers up to 5,859,000 shares issuable upon exercise of the pre‑funded and common warrants.
The common warrants become exercisable six months after issuance and expire five years from their initial exercise date; pre‑funded warrants are immediately exercisable at $0.0001. Gross proceeds are $5,277,994.10, placement agent fees are $316,680.00, and proceeds before expenses are $4,961,314.10. Craig‑Hallum Capital Group LLC is sole placement agent. Net proceeds are intended for research and development and general corporate purposes.
The company reports approximately $26.2 million of cash and cash equivalents for the three months ended September 30, 2025. Shares outstanding are expected to be 52,374,362 immediately after the offering. Certain February 2025 warrants to purchase up to 5,948,334 shares will have their exercise price reduced to $1.00, effective upon closing.